Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

Summary

The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of adolescents (aged 12 through 17 years) with Major Depressive Disorder (MDD).

Timeline

Start

2007-07

Primary completion

2010-10

Completion

2010-10

Publications

• Barac M, Nakonezny PA, Croarkin PE, Athreya AP, Jones SM, Hergert SM, Emslie GJ. Validation of the Brief Children's Depression Rating Scale in Children Treated With Selegiline Transdermal Patch vs Placebo. JAACAP Open. 2025 Dec 1;4(2):354-362. doi: 10.1016/j.jaacop.2025.11.010. eCollection 2026 Apr.

Drugs

Indications